Investigational drug · Phase 3
6-Thio-2'-Deoxyguanosine
Also called: 6-thio-dG, THIO, ateganosine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small -Cell Lung.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "6-Thio-2'-Deoxyguanosine"
First trial start
2022
Jun 8, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "6-Thio-2'-Deoxyguanosine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non-Small -Cell Lung
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "6-Thio-2'-Deoxyguanosine" as an intervention, largest first.
- A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCPivotal-lookingRecruiting
Maia BiotechnologyIndustry
NCT06908304 · 300 participants (planned) · Start Dec 8, 2025 · Primary completion Jul 31, 2027
Drug: 6-Thio-2'-Deoxyguanosine; Cemiplimab and 3 more · For: Carcinoma, Non-Small -Cell Lung
Sites: Poznan, Poland; Craiova, Romania; Timișoara, Romania · 15 sites in all
- THIO Sequenced With Cemiplimab in Advanced NSCLCPivotal-lookingActive, not recruiting
Maia BiotechnologyIndustry
NCT05208944 · 227 participants (planned) · Start Jun 8, 2022 · Primary completion Sep 30, 2027
Drug: 6-Thio-2'-Deoxyguanosine; Cemiplimab · For: Carcinoma, Non-Small-Cell Lung
Sites: Birmingham, Alabama; Florham Park, New Jersey; Buderim, Australia · 40 sites in all
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT07446257 · 60 participants (planned) · Start Sep 1, 2026 · Primary completion Sep 1, 2029
Drug: ateganosine; Cadonilimab · For: Resectable Hepatocellular Carcinoma
Sites: Dallas, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Selective and sensitive dual channel sensing of cyanide by bithiophene fluorophore-based D-π-A type chemodosimeters - Spectral and theoretical studies.
Abirami S, Dharaniprabha V, Ponlakshmi P, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
- Synthesis of thioglycoside-isochroman and thioglycoside-tryptoline conjugates via cryo thio-click and heterocyclization reactions and evaluation of their inhibitory activity against LecA and LecB lectins of Pseudomonas aeruginosa.
Ahmad N, Alnukari S, Homolya Á, et al. · Eur J Med Chem 2027
- Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1 treatment.
Höppner S, Werr L, Szilagyi B, et al. · Oncoimmunology 2026
- Exploring the role of conformational restriction in 5-alkyl-6-benzyl-2-{[(methylthio)methyl]thio}pyrimidin-4(3H)-ones: Effects in HIV-1 infected cells and reverse transcriptase enzymes.
Degtyarenko E, Hailu GS, Fabbrizi E, et al. · Eur J Med Chem 2026
- Synthesis of 2,3-dideoxy-C-3-thiopyrimidine based new Glycohybrids.
Sharma S, Shukla A, Sagar R · Carbohydr Res 2026
- Recent advances in anomeric C-S bond activation: Emerging opportunities for stereoselective glycosides.
Nandy A, Dwivedi S, Sau A · Carbohydr Res 2026
Also in development for Carcinoma, Non-Small-Cell Lung
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials
Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.